A recent inquiry by the Commerce department into the potential national security risks posed by pharmaceutical imports has sparked debate. While the investigation, known as a Section 232 investigation, aims to safeguard access to essential medications, critics argue that the proposed solution-imposing tariffs-could backfire, creating the very problems it seeks to prevent.

The core concern revolves around the idea that relying on imported medicines and ingredients makes the U.S. vulnerable. Proponents of tariffs suggest that foreign adversaries could disrupt the supply chain, potentially leading to geopolitical leverage and compromising national security.

Though, opponents contend that even if these concerns were valid, tariffs are not the answer. The Trump Administration, for instance, has previously considered tariffs of 25% or higher on imported drugs and active pharmaceutical ingredients should the Section 232 investigation determine vulnerabilities exist.

These tariffs, essentially taxes, would disproportionately affect patients, both directly and indirectly. Patients would face higher costs for both generic and brand-name medications,exacerbating affordability issues and potentially limiting access to necessary treatments.

Drug manufacturers would also bear some of the burden, with the ultimate impact varying depending on the type of medication.

Impact on Generic and Branded Medications

“A 25% tariff on imported medicines would significantly increase the costs of medicines in the U.S.”

Generic drug manufacturers, responsible for 90% of prescriptions in the U.S., operate on narrow margins. With most generic drugs costing $20 or less and average patient co-pays around $6,tariffs on imported ingredients would significantly increase production costs.

This could weaken the generic manufacturing base, potentially leading to reduced access to affordable medications.Tariffs on imported pharmaceutical ingredients, crucial for many domestic generic manufacturers, would further compound the problem, driving up costs and decreasing the availability of low-cost generic drugs.

Ultimately, tariffs could make domestic generic drug production less profitable, discouraging efforts to increase local manufacturing.

The impact on brand-name drug manufacturers is equally concerning. The U.S. is a global leader in biopharmaceutical innovation. The industry invested $141 billion in research and advancement in 2022,contributing significantly to the U.S. economy.

Beyond economic contributions, innovative medicines have improved health outcomes for patients with conditions like cancer and autoimmune diseases. Ongoing innovation offers hope for those with currently untreatable diseases, such as Alzheimer’s.

tariffs would increase costs for brand-name manufacturers, making it harder to justify investments in developing new medicines, which are estimated to cost $2.9 billion, including post-approval research and development.This could reduce the likelihood of developing effective treatments for unmet medical needs.

Critics also argue that the national security concerns are based on a flawed understanding of the pharmaceutical supply chain. A meaningful portion of innovative medicines used in the U.S. are already “produced in the United States.” Furthermore, imported drugs and ingredients primarily come from U.S. allies in europe, posing no national security threat.

manufacturers utilize the global supply chain to produce high-quality, safe drugs cost-effectively.Even if tariffs incentivized domestic production, patients would likely face higher medicine costs, resulting in a less efficient and more expensive biopharmaceutical industry.

Rather of tariffs, the Administration could incentivize domestic manufacturing by reducing regulatory burdens that inflate U.S. drug manufacturing costs.

A 25% tariff on imported medicines would significantly increase costs and create access issues for patients,especially those with low incomes and inadequate insurance. If the Section 232 investigation incorrectly concludes that the global supply chain threatens patient access,the resulting tariffs would create the very problems they aim to solve.